MedTrace Logo

High Altitude Residents With High Altitude Pulmonary Hypertension (HAPH), SDB Assessed at HA (3200 m) vs LA (760 m)

NCT06489717 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-01-22

No results posted yet for this study

Summary

To study the effect of relocation from 3200m (Aksay) to 760m (Bishkek) in highlanders with High Altitude Pulmonary Hypertension (HAPH) who permanently live \>2500m on sleep disordered breathing

Conditions

  • High Altitude Pulmonary Hypertension

Interventions

OTHER

SDB assessment

SDB will be assessed by respiratory polygraphy according to clinical standards

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Talant M Sooronbaev, Prof. Dr. · National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

  • Silvia Ulrich, Prof. Dr. · University Hospital Zurich, Department of Pulmonology

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-02
Primary Completion
2024-07-12
Completion
2024-07-12

Countries

  • Kyrgyzstan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06489717 on ClinicalTrials.gov